Concentrations of besifloxacin, gatifloxacin, and moxifloxacin in human conjunctiva after topical ocular administration.
OBJECTIVE
To evaluate the pharmacokinetic properties of besifloxacin, gatifloxacin, and moxifloxacin in the conjunctival tissue of healthy volunteers after topical application.


METHODS
One-hundred eight (108) subjects were randomly assigned to receive one drop of besifloxacin (0.6% suspension), gatifloxacin (0.3% solution), or moxifloxacin (0.5% solution) ophthalmic formulations in one eye prior to conjunctival biopsy. Conjunctival samples were taken from subjects at either 15 minutes, 30 minutes, 2 hours, 6 hours, 12 hours, or 24 hours after dosing.


RESULTS
All three fluoroquinolones reached a peak mean concentration 15 minutes after dosing. The mean concentrations of besifloxacin, gatifloxacin, and moxifloxacin at 15 minutes were 2.30 +/- 1.42 mug/g, 4.03 +/- 3.84 mug/g, and 10.7 +/- 5.89 mug/g, respectively. Concentrations decreased with each subsequent time point. At 24 hours after dosing, concentrations of besifloxacin were measurable in 4 of 6 subjects, compared with 3 of 6 subjects for gatifloxacin and 2 of 6 subjects for moxifloxacin. Besifloxacin had the greatest mean residence time (4.7 hours) in the conjunctival tissue. With regard to methicillin-resistant strains of Staphylococcus aureus and Staphylococcus epidermidis, besifloxacin had the greatest area-under-the-curve (AUC) to MIC(90) ratio. Nine percent (9%) of study subjects (N = 7) experienced a transient reduction in visual acuity.


CONCLUSIONS
All three fluoroquinolones were well tolerated and reached levels in the conjunctiva above the MIC(90)s of methicillin-sensitive S. aureus and S. epidermidis for at least 2 hours.
Torkildsen
Gail
G
Andover Eye Associates, Andover, Massachusetts, USA.
Proksch
Joel W
JW
Shapiro
Aron
A
Lynch
Stephanie K
SK
Comstock
Timothy L
TL
Antimicrob Agents Chemother. 2003 Sep;47(9):2749-55
12936969
Clin Pharmacokinet. 1995 Feb;28(2):143-60
7736689
Acta Ophthalmol. 2008 Feb;86(1):5-17
17970823
J Ocul Pharmacol Ther. 2008 Dec;24(6):587-91
19049265
J Antimicrob Chemother. 2009 Mar;63(3):443-50
19147516
J Ocul Pharmacol Ther. 2003 Oct;19(5):493-9
14583139
Antimicrob Agents Chemother. 1993 May;37(5):1073-81
8517694
Cochrane Database Syst Rev. 2006 Apr 19;(2):CD001211
16625540
J Antimicrob Chemother. 2000 Nov;46(5):669-83
11062185
Antimicrob Agents Chemother. 2001 Oct;45(10):2793-7
11557471
Curr Med Res Opin. 2009 May;25(5):1159-69
19323612
J Ocul Pharmacol Ther. 2009 Apr;25(2):133-9
19284320
Antimicrob Agents Chemother. 2007 Apr;51(4):1315-20
17296740
J Pharmacol Exp Ther. 1998 Jul;286(1):29-35
9655838
Clin Ther. 2008 Nov;30(11):2005-14
19108788
Surv Ophthalmol. 2005 Nov;50 Suppl 1:S32-45
16257309
J Chromatogr B Analyt Technol Biomed Life Sci. 2008 May 1;867(1):105-10
18417430
Arch Ophthalmol. 2005 Sep;123(9):1282-3
16157821
J Ocul Pharmacol Ther. 2009 Aug;25(4):335-44
19492955
Clin Ther. 2009 Mar;31(3):514-26
19393842
Ophthalmologe. 1995 Dec;92(6):793-801
8563427
Am J Ophthalmol. 2008 Jun;145(6):951-958
18374299